Eventually transition to maintenance when you've reached your goals
But the FDA has restricted the mass compounding of GLP-1s for safety and regulatory concerns
ADJUNCT TWO was a 26-week, double-blind, parallel-group trial with 835 people randomised 3:1 to liraglutide or placebo (Ahrn et al, 2016)
Also, due to the important role of endothelial dysfunction in CVD, the effects of GLP-1RA on flow-mediated vasodilation (FMD) in patients remain to be investigated for their contribution to the CVD actions of GLP-1RAs
This raises concerns about unsupervised use and highlights the need for caution until more safety data becomes available (2 Trusted Source Retatrutide-A Game Changer in Obesity Pharmacotherapy Go to source)
For GLP-1 users who want microbiome support without the gastrointestinal drama, acacia fiber is worth serious consideration